Cardiovascular Risk
- NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see
WARNINGS).
- FELDENE® is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see
WARNINGS).
Gastrointestinal Risk
- NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see
WARNINGS).
|
| |
FELDENE SUMMARY
Cardiovascular Risk
FELDENE contains piroxicam which is a member of the oxicam group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each maroon and blue capsule contains 10 mg piroxicam, each maroon capsule contains 20 mg piroxicam for oral administration.
Carefully consider the potential benefits and risks of FELDENE and other treatment options before deciding to use FELDENE. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).
FELDENE is indicated:
- For relief of the signs and symptoms of osteoarthritis.
- For relief of the signs and symptoms of rheumatoid arthritis.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Feldene (Piroxicam)
Immunomodulatory effect of NSAID in geriatric patients with acute infection: effects of piroxicam on chemokine/cytokine secretion patterns and levels of heat shock proteins. A double-blind randomized controlled trial. (ISRCTN58517443). [2011.11.05]
Inflammation in older persons is associated with frailty, cachexia, and disability. We hypothesized that NSAID treatment in addition to antibiotics in older patients with acute infection might rapidly reduce inflammatory cytokines and might be of therapeutic potential to improve outcomes... Further studies are needed to establish whether these effects can change functional outcomes in geriatric patients.
Sublingual piroxicam in migraine without aura. [2011.08]
OBJECTIVE: The aim of the present study was to compare the analgesic efficacy of a single dose of sublingual piroxicam to that of a placebo during acute attacks of migraine without aura... CONCLUSIONS: The present study has demonstrated that for the acute management of migraine without aura sublingual piroxicam showed significant analgesic effect with excellent tolerability.
Comparison of oral versus sublingual piroxicam during postoperative pain management after lower third molar extraction. [2011.03]
In this study, 53 patients received piroxicam, administered orally or sublingually, after undergoing removal of symmetrically positioned lower third molars, during two separate appointments...
Paracetamol vs piroxicam to relieve pain in renal colic. Results of a randomized controlled trial. [2011.02]
PURPOSE: We tested whether paracetamol could improve pain relief in patients visiting the emergency department with acute renal colic as compared to piroxicam, a nonsteroidal anti-inflammatory drug (NSAID)... CONCLUSION: A single therapy with intravenous paracetamol more efficiently relieved pain in acute renal colic than did intramuscular piroxicam. Copyright A(c) 2011 Elsevier Inc. All rights reserved.
Effects on muscle performance of NSAID treatment with piroxicam versus placebo in
geriatric patients with acute infection-induced inflammation. A double blind
randomized controlled trial. [2011]
cytoprotective Hsp... CONCLUSIONS: Piroxicam improves clinically relevant measures of muscle
Reports of Suspected Feldene (Piroxicam) Side Effects
Hypersensitivity (4),
Headache (4),
Developmental Delay (4),
Gastrooesophageal Reflux Disease (4),
Duane's Syndrome (4),
Cleft LIP and Palate (4),
Drug Hypersensitivity (4),
Torticollis (4),
Craniosynostosis (4),
Feeding Disorder (4), more >>
|
|
|
|
Page last updated: 2013-02-10
|
